LIST OF COMMENTERS

Abbreviation	Name
Allegheny	Allegheny Power and Allegheny Energy Supply Company, L.L.C.
AGA	American Gas Association.
APPA and TAPS	American Public Power Association and Transmission Access Policy Study Group.
Butte County	Butte County, California.
California Resources	California Resources Agency.
California State Agencies	California Coastal Commission, California Energy Commission, California Electricity Oversight Board, and California State Lands Commission.
Dominion	Dominion Transmission Inc., Dominion Cove Point, LNG, LP, and Dominion South Pipeline Company, LP.
EEI	Edison Electric Institute.
INGAA	Interstate Natural Gas Association of America.
MidAmerican	MidAmerican Energy Company.
NARUC	National Association of Regulatory Utility Commissioners.
NHA	National Hydropower Association.
SCE	Southern California Edison Company.
Western Energy Board	Western Interstate Energy Board and Committee on Regional Electric Power Cooperation.
Williston Basin	Williston Basin Interstate Pipeline Company.
Department of the Interior	United States Department of the Interior.

[FR Doc. E7–22141 Filed 11–13–07; 8:45 am]
BILLING CODE 6717–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 510

New Animal Drugs; Change of Sponsor's Address

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor address for IDEXX Pharmaceuticals, Inc.

DATES: This rule is effective November 14, 2007.

FOR FURTHER INFORMATION CONTACT: David R. Newkirk, Center for Veterinary Medicine (HFV–100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6967, e-mail: *david.newkirk@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION: IDEXX Pharmaceuticals, Inc., 4249–105 Piedmont Pkwy., Greensboro, NC 27410, has informed FDA of a change of address to 7009 Albert Pick Rd., Greensboro, NC 27409. Accordingly, the agency is amending the regulations in 21 CFR 510.600(c) to reflect the change.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

PART 510—NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. In § 510.600, in the table in paragraph (c)(1) revise the entry for ''IDEXX Pharmaceuticals, Inc.''; and in the table in paragraph (c)(2) revise the entry for ''065274'' to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

* * * * *

(c) * * *

(1) * * *

Firm name and address	Drug labeler code
* * *	* *
IDEXX Pharmaceuticals, Inc., 7009 Albert Pick Rd., Greensboro, NC 27409.	065274
* * *	* *

(2) * * *

Drug labeler code	Firm name and address
* * *	* *
065274	IDEXX Pharmaceuticals, Inc., 7009 Albert Pick Rd., Greensboro, NC 27409
* * *	* *

Dated: November 6, 2007.

Bernadette Dunham,

Deputy Director, Center for Veterinary Medicine.

[FR Doc. E7–22210 Filed 11–13–07; 8:45 am]
BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Chlortetracycline Powder

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Fort Dodge Animal Health, Division of Wyeth Holdings Corp. The supplemental NADA provides for label revisions for chlortetracycline soluble powder.

DATES: This rule is effective November 14, 2007.

FOR FURTHER INFORMATION CONTACT: Joan C. Gotthardt, Center for Veterinary Medicine (HFV–130), Food and Drug Administration, 7500 Standish Pl.,

Rockville, MD 20855, 301–827–7571, e-mail: *joan.gotthardt@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION: Fort Dodge Animal Health, Division of Wyeth Holdings Corp., P.O. Box 1339, Fort Dodge, IA 50501, filed a supplement to NADA 65–440 for AUREOMYCIN (chlortetracycline) Soluble Powder Concentrate, approved for oral use in medicated drinking water of chickens, growing turkeys, swine, calves, beef cattle, and nonlactating dairy cattle for the control and/or treatment of various bacterial diseases. The supplemental NADA provides for label revisions. The supplemental application is approved as of October 18, 2007, and the regulations are amended in 21 CFR 520.445b to reflect the approval.

Approval of this supplemental NADA did not require review of additional safety or effectiveness data or information. Therefore, a freedom of information summary is not required.

The agency has determined under § 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Parts 520

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 2. In § 520.445b, revise paragraph (b)(2) and add paragraph (d)(5) to read as follows:

§ 520.445b Chlortetracycline powder.

* * * * *

(b) * * *

(2) No. 053501 for use as in paragraph (d)(5) of this section.

* * * * *

(d) * * *

(5) Use in a drench or drinking water as follows:

(i) *Chickens*—(A) *Amount.* 200 to 400 mg/gal, for 7 to 14 days.

(*1*) *Indications for use.* Control of infectious synovitis caused by *M. synoviae* susceptible to chlortetracycline.

(*2*) *Limitations.* Prepare fresh solution daily; use as the sole source of chlortetracycline; do not use for more than 14 consecutive days; do not use in laying chickens; do not administer to chickens within 24 hours of slaughter.

(B) *Amount.* 400 to 800 mg/gal, for 7 to 14 days.

(*1*) *Indications for use.* Control of chronic respiratory disease (CRD) and air-sac infections caused by *M. gallisepticum* and *E. coli* susceptible to chlortetracycline.

(*2*) *Limitations.* As in paragraph (d)(5)(i)(A)(*2*) of this section.

(C) *Amount.* One thousand mg/gal, for 7 to 14 days.

(*1*) *Indications for use.* Control of mortality due to fowl cholera caused by Pasteurella multocida susceptible to chlortetracycline.

(*2*) *Limitations.* As in paragraph (d)(5)(i)(A)(*2*) of this section.

(ii) *Growing Turkeys*—(A) *Amount.* 400 mg/gal, for 7 to 14 days.

(*1*) *Indications for use.* Control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline.

(*2*) *Limitations.* Prepare fresh solution daily; use as the sole source of chlortetracycline; do not use for more than 14 consecutive days; do not administer to growing turkeys within 24 hours of slaughter.

(B) *Amount.* 25 mg/lb body weight daily, for 7 to 14 days.

(*1*) *Indications for use.* Control of complicating bacterial organisms associated with bluecomb (transmissible enteritis, coronaviral enteritis) susceptible to chlortetracycline.

(*2*) *Limitations.* As in paragraph (d)(5)(ii)(A)(*2*) of this section.

(iii) *Swine*—(A) *Amount.* 10 mg/lb body weight daily, for 3 to 5 days.

(B) *Indications for use.* Control and treatment of bacterial enteritis (scours) caused by *E. coli* and Salmonella spp., and bacterial pneumonia associated with Pasteurella spp., *A. pleuropneumoniae*, and *Klebsiella* spp. susceptible to chlortetracycline.

(C) *Limitations.* Prepare fresh solution daily; use as the sole source of chlortetracycline; do not use for more than 5 days; do not administer to swine within 24 hours of slaughter.

(iv) *Calves, beef cattle, and nonlactating dairy cattle*—(A) *Amount.* 10 mg/lb body weight daily in divided doses, for 3 to 5 days.

(B) *Indications for use.* Control and treatment of bacterial enteritis (scours) caused by Escherichia coli and Salmonella spp., and bacterial pneumonia associated with Pasteurella spp., *Histophilus* spp., and *Klebsiella* spp. susceptible to chlortetracycline.

(C) *Limitations.* Prepare fresh solution daily; use as a drench; use as the sole source of chlortetracycline; do not use for more than 5 days; do not administer to cattle within 24 hours of slaughter; do not use in lactating dairy cattle; do not administer this product with milk or milk replacers; administer 1 hour before or 2 hours after feeding milk or milk replacers; a withdrawal period has not been established in preruminating calves; do not use in calves to be processed for veal.

Dated: November 2, 2007.

Bernadette Dunham,

Deputy Director, Center for Veterinary Medicine.

[FR Doc. E7–22261 Filed 11–13–07; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF DEFENSE

Office of the Secretary

[DOD–2007–HA–0118]

32 CFR Part 199

TRICARE, Formerly Known as the Civilian Health and Medical Program of the Uniformed Services (CHAMPUS); Coverage of Physician Assistant Services

AGENCY: Department of Defense.

ACTION: Administrative correction.

SUMMARY: This action corrects the reference to a re-designated paragraph within this part regarding the allowable charge for physician assistant services. This document is published to improve the accuracy of 32 CFR part 199.

DATES: *Effective Dates:* November 14, 2007.

ADDRESSES: TRICARE Management Activity, 16401 East Centretech Parkway, Aurora, CO 80011.

FOR FURTHER INFORMATION CONTACT: Michael Kottyan, Office of Medical Benefits and Reimbursement Systems, TRICARE Management Activity, telephone (303) 676–3520.

SUPPLEMENTARY INFORMATION: The final rule published in the **Federal Register** on August 1, 1990 (55 FR 31179) provided the authority for CHAMPUS payment of services rendered by physician assistants (PA) and included a reference to a paragraph elsewhere in this part. Subsequent actions re-designated that paragraph. This action